Stocklytics Platform
Asset logo for symbol CRNX
Crinetics Pharmaceuticals
CRNX52
$53.67arrow_drop_up1.62%$0.86
Asset logo for symbol CRNX
CRNX52

$53.67

arrow_drop_up1.62%

Performance History

Chart placeholder
Key Stats
Open$53.44
Prev. Close$52.81
EPS-3.77
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$4.16B
PE Ratio-
LOWHIGH
Day Range52.59
54.57
52 Week Range15.76
54.57
Ratios
P/B Ratio6.45
Revenue$4.01M
Operating M. %-11,488.91%
Earnings$0.00
Earnings Growth %-30.88%
EBITDA Margin %-1,000.00%
ROE %-40.76%
EPS-3.77

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

Correlated Companies

Price$948.40
Perf. (24h)
arrow_drop_up1.52%$14.26
Market Cap$841.10B
Price$511.53
Perf. (24h)
arrow_drop_up1.42%$7.17
Market Cap$464.20B
Price$149.88
Perf. (24h)
arrow_drop_up0.12%$0.18
Market Cap$360.27B
Price$127.76
Perf. (24h)
arrow_drop_down0.93%-$1.21
Market Cap$326.65B

About Crinetics Pharmaceuticals (CRNX)

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for endocrine diseases and endocrine-related tumors. The company's lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). It is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. The company was incorporated in 2008 and is headquartered in San Diego, California.

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. R. Scott Struthers Ph.D.
Headquarters
San Diego
Employees
210
Exchange
NASDAQ
add Crinetics Pharmaceuticals  to watchlist

Keep an eye on Crinetics Pharmaceuticals

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is Crinetics Pharmaceuticals 's (CRNX) price per share?

The current price per share for Crinetics Pharmaceuticals (CRNX) is $53.67. The stock has seen a price change of $0.86 recently, indicating a 1.63% change. This reflects the stock's recent market performance and investor sentiment.

help
What is the 52-week high and low for Crinetics Pharmaceuticals (CRNX)?

For Crinetics Pharmaceuticals (CRNX), the 52-week high is $54.57, which is 1.68% from the current price. The 52-week low is $15.76, the current price is 240.55% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help
Is Crinetics Pharmaceuticals (CRNX) a growth stock?

Crinetics Pharmaceuticals (CRNX) has shown an average price growth of 0.41% over the past three years. It has received a score of 91 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Crinetics Pharmaceuticals as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help
What is Crinetics Pharmaceuticals (CRNX) stock price performance year to date (YTD)?

As of the latest data, Crinetics Pharmaceuticals (CRNX) has a year-to-date price change of 51.65%. Over the past month, the stock has experienced a price change of 14.46%. Over the last three months, the change has been 22.87%. Over the past six months, the figure is 43.89%. Looking at a longer horizon, the five-year price change stands at 122.24%.

help
Is Crinetics Pharmaceuticals (CRNX) a profitable company?

Crinetics Pharmaceuticals (CRNX) has a net income of -$214.53M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 72.64% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -11.49K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $4.01M, although specific revenue growth data is currently not available. The gross profit is $2.92M. Operating income is noted at -$222.61M. Furthermore, the EBITDA is -$246.87M.

help
What is the market capitalization of Crinetics Pharmaceuticals (CRNX)?

Crinetics Pharmaceuticals (CRNX) has a market capitalization of $4.16B. The average daily trading volume is 1.25M, indicating the stock's liquidity and investor engagement.

News

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level